Hyperphosphatemia in uremic patients is associated with metastatic calcification such as tumoral calcinosis and vascular calcification, and an increased cardiovascular mortality and morbidity.[@b1-asm-6-469a] To avoid hyperphosphatemia-related complications, the use of oral phosphate-binding agents is universal to reduce phosphate absorption in the gastrointestinal tract. "Old generation" phosphate binders with aluminum or calcium-based agents tend to cause neurological toxicity and exacerbation of calcium overloading and soft tissue or cardiovascular calcification, respectively.[@b2-asm-6-469a] The "new generation" of aluminum or calcium-free phosphate binders has been shown to effectively control serum phosphate concentration with the attenuation of cardiovascular and soft tissue calcification.

Lanthanum carbonate (La~2~(CO~3~)~3~), is a novel calcium-and aluminum-free phosphate binder for the treatment of hyperphosphatemia in ESRD patients. The element, lanthanum (La, atomic number 57, atomic weight 138.9) is a rare-earth natural metal belonging to group 3B of the periodic table and causes radiopacities in the roentgenogram, as does barium (atomic number 56) ([Figure 1](#f1-asm-6-469a){ref-type="fig"}). The half-life of lanthanum elimination from plasma is 53 hours though the plasma level is extremely low and elimination half-life from bone is 2.0 to 3.6 years.[@b3-asm-6-469a] The affinity of lanthanum compound for phosphate is \>97% and is more potent than calcium or magnesium, and similar to aluminum.[@b4-asm-6-469a] Lanthanum binds phosphate optimally at pH 3\~5 and retains binding activity at pH 1\~7.[@b5-asm-6-469a] It is virtually non-absorbed (0.00005%) and chelates dietary phosphate into insoluble lanthanum phosphate by ionized form. Lanthanum phosphate and carbonate in the gut may form numerous radiopaque spots on the abdominal x-ray, which is not reported with other phosphate binders.[@b6-asm-6-469a],[@b7-asm-6-469a]

These unexpected starry opacities disappear completely after the withdrawal of lanthanum carbonate. The patient continued lanthanum carbonate treatment because of no abdominal symptoms and improved pain. Due to this radiopaque feature, one can evaluate the compliance to this drug. Given the increasing usage of lanthanum carbonate in patients with ESRD, every physician must understand this typical benign radiopaque finding to avoid unnecessary examination and inappropriate management.

![Radiopaque lanthanum carbonate tablets milled in the gastrointestinal distribution. Starry opacities also seen.](asm-6-469af1){#f1-asm-6-469a}
